secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001171843-24-002452
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus CSO Michael Sofia to retire Dec 31, 2024; no successor named yet.
-------------------------------------------------------------------------

- Dr. Michael Sofia, co-founder and Chief Scientific Officer, notified retirement effective December 31, 2024.
- Sofia is a Lasker award-winning antiviral drug discovery scientist with 38-year career.
- Interim CEO Michael McElhaugh thanked Sofia for contributions to HBV functional cure development.
- No replacement for CSO role announced; company continues clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324002452/0001171843-24-002452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324002452/f8k_050124.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer